CAAR-T cells for treating PV, which consists of the PV autoantigen desmoglein (Dsg)3, can specifically eliminate autoreactive B cells expressing anti-Dsg3 B-cell receptors, resulting in potent cytotoxicity in vitro and in vivo without off-target effects. Here, DSG3 is linked to acquired polycythemia vera.